Skip to main content
Caplight Logo









Pragma Bio

Pragma Bio

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.pragmabio.com/

Last Round

Series A

Mar 23, 2023

Total Funding Raised

$14.5M

Company Overview

Pragma Bio is a biotechnology company that uses an AI-powered platform and synthetic biology to discover and develop small molecule medicines derived from the human gut microbiome for immunological disorders.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoverymicrobiome therapeuticssynthetic biologymetagenomicsAI drug discoverygut-immune axisin silico drug discoverybiomanufacturingai biotechmicrobiome miningbiosynthetic gene clustersBGCsmall molecule discoverybioinformaticsprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pragma Bio Comparables

Compare Pragma Bio with similar companies based on industry and business-model similarity.

Pragma Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Wild Biotech
82%
Hexagon Bio
82%
Persephone Biosciences
82%

Pragma Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 23, 2023
SeedDec 15, 2020

Key People

Founding team and executive leadership

Mohamed Donia

Scientific Co-Founder And Chief Scientific Officer

Founding Team

Peter McCaffrey

CTO, Co-Founder

Founding Team

Pragma Bio Investors

Notable investors and investment history

Pragma Bio investors
InvestorRounds
CJ InvestmentSeed
Viking Global InvestorsSeries A, Seed
The Venture CollectiveSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 23, 2023

    $10M round led by The Venture Collective.

  • Dec 15, 2020

    $5M round led by Viking Global Investors

Pragma Bio Filings

Explore SEC and related filing metadata, where available.

Pragma Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Pragma Bio's valuation, stock price, and market status.

Is Pragma Bio a public or private company?

Pragma Bio is a private company.

What is the current stock price of Pragma Bio?

Pragma Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Pragma Bio worth (valuation)?

Valuation information for Pragma Bio is not publicly available.

Can I buy Pragma Bio stock?

Pragma Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Pragma Bio's last funding round?

Pragma Bio's most recent funding round was Series A on March 23, 2023.

Who are the main investors in Pragma Bio?

Key investors in Pragma Bio include Viking Global Investors, The Venture Collective.

Will Pragma Bio IPO soon?

No public IPO plans have been announced for Pragma Bio.

How can I track Pragma Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Pragma Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range15
Year Founded2018
Last FundingMar 23, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?